News
MDWD
16.65
+2.46%
0.40
Weekly Report: what happened at MDWD last week (0504-0508)?
Weekly Report · 3d ago
MediWound to report first-quarter 2026 results, hosts conference call and webcast
PUBT · 05/07 12:00
MediWound Shareholders Back Board, Auditor and CEO Bonus at 2026 Annual Meeting
TipRanks · 05/06 20:34
Weekly Report: what happened at MDWD last week (0427-0501)?
Weekly Report · 05/04 09:55
Weekly Report: what happened at MDWD last week (0420-0424)?
Weekly Report · 04/27 09:57
MediWound Gains Attention from Wound Care Leaders as EscharEx Takes On Legacy SANTYL in $2.5B Market
TipRanks · 04/23 14:00
Weekly Report: what happened at MDWD last week (0413-0417)?
Weekly Report · 04/20 09:54
MediWound: EscharEx Phase III Upside and NexoBrid Traction Support Compelling Buy Thesis
TipRanks · 04/13 19:25
Weekly Report: what happened at MDWD last week (0406-0410)?
Weekly Report · 04/13 09:57
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
Barchart · 04/13 06:30
Analysts Offer Insights on Healthcare Companies: Mediwound (MDWD) and ImmunityBio (IBRX)
TipRanks · 04/09 17:30
MediWound Showcases New Wound Healing Data Across 3 Global Conferences, EscharEx Study Results Back Late-Stage Trials And Expansion Into Diabetic Ulcers
Benzinga · 04/07 11:03
MediWound presents new EscharEx data backing Phase III VALUE trial in venous leg ulcers
Reuters · 04/07 11:01
Analysts Offer Insights on Healthcare Companies: Simulations Plus (SLP) and Mediwound (MDWD)
TipRanks · 04/06 14:10
Weekly Report: what happened at MDWD last week (0330-0403)?
Weekly Report · 04/06 09:57
MediWound Highlights Vericel’s $197 Million BARDA Contract for NexoBrid
TipRanks · 04/02 21:21
MediWound says Vericel awarded ten-year contract valued at up to $197M
TipRanks · 04/02 19:37
MediWound says Vericel wins BARDA contract for NexoBrid worth up to $197 million
Reuters · 04/02 19:26
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
Barchart · 04/02 14:26
MediWound Sets May 6, 2026 Shareholder Meeting to Vote on Board, Auditor and CEO Bonus
TipRanks · 03/30 22:40
More
Webull provides a variety of real-time MDWD stock news. You can receive the latest news about Mediwound through multiple platforms. This information may help you make smarter investment decisions.
About MDWD
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.